Interleukin 8 and 1β and RANTES levels in esophageal mucosa predict recurrence of endoscopy-negative gastroesophageal reflux disease

Hepato-Gastroenterology

Volumn 55, Issue 82-83, 2008, Pages 482-485

  Isomoto, Hajime ^a   Wang, Aiping ^a   Nishi, Yoshito ^a   Matsumoto, Ayako ^a   Shikuwa, Saburo ^a   Mizuta, Yohei ^a   Inoue, Kenichiro ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shunkaikai Inoue Hospital   (Japan)

Author keywords

Endoscopy negative GERD; Interleukin 8 and 1 ; RANTES; Recurrence

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 8; LANSOPRAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECURRENT DISEASE; SMOKING HABIT; T LYMPHOCYTE ACTIVATION; CHEMISTRY; ESOPHAGUS; IMMUNOLOGY; MIDDLE AGED; MUCOSA; PREDICTION AND FORECASTING;

ADULT; AGED; CHEMOKINE CCL5; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 44349187353     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kobayashi S, Kasugai T: Endoscopic and biopsy criteria for the diagnosis of esophagitis with a fibreoptic esophagoscope. Dig Dis 1974; 19:345-352.
2. Frierson HF Jr: Histology in the diagnosis of reflux esophagitis. Gastroenterol Clin N Am 1990; 19:631-644.
3. Lundell LR, Dent J, Bennett JR, et al: Endoscopic assessment of esophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:631-644.
4. Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R: The pathophysiology of gastro-oesophageal reflux disease-oesophageal manifestations. Aliment Pharmacol Ther 2004; 20:14-25. (Review article)
5. Donnellan C, Sharma N, Preston C, Moayyedi P: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2:CD003245.
6. Heading R: Epidermiology of oesophageal reflux disease. Scand J Gastroenterol 1989; 24:25-36.
7. Winters C, Spurling T, Chobanian S et al: Barrett's esophagus: A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92:118-124.
8. Spechler SJ, Zeroogian JM, Antonioli DA et al:. Prevalence of metaplasia at the gastro-esophageal junction. Lancet 1994; 344:1533-1536.
9. Cameron A, Kamath P, Carpenter H: Prevalence of Barrett's esophagus and intestinal metaplasia at the esophagogastric junction. Gastroenterology 1997; 112:A82.
10. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ: Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002; 50:451-459.
11. Isomoto H, Wang A, Mizuta Y, Akazawa Y, Ohba K, Omagari K, Miyazaki M, Murase K, Hayashi T, Inoue K, Murata I, Kohno S: Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am J Gastroenterol 2003; 98:551-556.
12. Isomoto H, Nishi Y, Wang A, Takeshima F, Omagari K, Mizuta Y, Shikuwa S, Murata I, Kohno S: Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux. Am J Gastroenterol 2004; 99:1063-1068.
13. Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, Farthing MJ: Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002; 51:316-322.
14. Chey WD: Endoscopy-negative reflux disease: concepts and clinical practice. Am J Med 2004; 117:S36-S43.
15. Pilotto A, Franceschi M, Leandro G, Novello R, Di Mario F, Valerio G: Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study. Am J Ther 2002; 9:295-300.
16. Baggiolini M, Loetscher P, Moser B: Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995; 17:103-108.
17. Mukaida N, Harada A, Matsushima K: Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998; 9:9-23.
18. Isomoto H, Mizuta Y, Miyazaki M, Takeshima F, Omagari K, Murase K, Nishiyama T, Inoue K, Murata I, Kohno S: Expression of nuclear factor κB in Helicobacter pylori-infected gastric mucosa detected with Southwestern histochemistry. Scand J Gastroenterol 2000; 35:247-254.
19. Caviglia R, Ribolsi M, Maggiano N, Gabbrielli AM, Emerenziani S, Guarino MP, Carotti S, Habib FI, Rabitti C, Cicala M: Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100:543-548.
20. Barlow WJ, Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005; 128:771-778.
21. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A: Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115:3057-3071.
22. Kim TH, Stone MA, Rahman P, Yoo DH, Park YW, Payne U, Hallett D, Inman RD: Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. J Rheumatol 2005; 32:1907-1910.
23. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
24. Bak YT: Management strategies for gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19:S49-S53.